Efficient gene transfer to airway epithelium using recombinant Sendai virus
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Clinical studies of gene therapy for cystic fibrosis (CF) suggest that the key problem is the efficiency of gene transfer to the airway epithelium. The availability of relevant vector receptors, the transient contact time between vector and epithelium, and the barrier function of airway mucus contribute significantly to this problem. We have recently developed recombinant Sendai virus (SeV) as a new gene transfer agent. Here we show that SeV produces efficient transfection throughout the respiratory tract of both mice and ferrets in vivo, as well as in freshly obtained human nasal epithelial cells in vitro. Gene transfer efficiency was several log orders greater than with cationic liposomes or adenovirus. Even very brief contact time was sufficient to produce this effect, and levels of expression were not significantly reduced by airway mucus. Our investigations suggest that SeV may provide a useful new vector for airway gene transfer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although both methods have low reprogramming efficiency, Sendai virus-mediated reprogramming has been used for several clinical applications, notably, in cystic fibrosis, the AIDS vaccine, and other iPSC replacement therapies [29,30,31,32,33].”
From Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies (2023) · cites this paper as [29]
Citations
Cites
Fuerst, T. R., Niles, E. G., Studier, F. W., & Moss, B. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.21.8122 · Cited by 2,089 · cited 1×
“Recombinant SeVs were constructed and propagated as previously describe”
MethodLiposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis
Caplen, N. J., Alton, E. W. F. W., Mddleton, P. G., Dorin, J. R., Stevenson, B. J., Gao, X., Durham, S. R., Jeffery, P. K., Hodson, M. E., Coutelle, C., et al. (1995) · Nature Medicine · doi:10.1038/nm0195-39 · Cited by 711
Zabner, J., Couture, L. A., Gregory, R. J., Graham, S. M., Smith, A. E., & Welsh, M. J. (1993) · Cell · doi:10.1016/0092-8674(93)80063-k · Cited by 681
Submucosal glands are the predominant site of CFTR expression in the human bronchus
Engelhardt, J. F., Yankaskas, J. R., Ernst, S. A., Yang, Y., Marino, C. R., Boucher, R. C., Cohn, J. A., & Wilson, J. M. (1992) · Nature Genetics · doi:10.1038/ng1192-240 · Cited by 653 · cited 1×
“2E ), the predominant site of CFTR expression in the human bronchu”
BackgroundLee, E. R., Marshall, J., Siegel, C. S., Jiang, C., Yew, N. S., Nichols, M. R., Nietupski, J. B., Ziegler, R. J., Lane, M. B., Wang, K. X., et al. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.14-1701 · Cited by 443 · cited 1×
“, or the plasmid pCMV-luc complexed to GL-67/DOPE/DMPE-PEG 5000 (80 μg DNA/mouse) were placed as a single 100 μl bolus into the nasal cavity of male BALB/c mice (six to eight weeks), and the solution was sniffed into the lung”
MethodEfficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis
Johnson, L. G., Olsen, J. C., Sarkadi, B., Moore, K. L., Swanstrom, R., & Boucher, R. C. (1992) · Nature Genetics · doi:10.1038/ng0992-21 · Cited by 439 · cited 1×
“Laboratory studies suggest that correction of the CF chloride defect can be achieved by introducing ∼6–10% of corrected cells overexpressing CFTR into a CF monolaye”
BackgroundAlton, E., Stern, M., Farley, R., Jaffe, A., Chadwick, S., Phillips, J., Davies, J., Smith, S., Browning, J., Davies, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)06532-5 · Cited by 435
Porteous, D., Dorin, Jr., McLachlan, G., Davidson-Smith, H., Davidson, H., Stevenson, B., Carothers, A., Wallace, W., Moralee, S., Hoenes, C., et al. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300390 · Cited by 324
Specific gangliosides function as host cell receptors for Sendai virus.
Markwell, M. A., Svennerholm, L., & Paulson, J. C. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5406 · Cited by 259 · cited 1×
“The receptor for SeV is sialic acid bound to gangliosides, present on most cell types, including the apical surface of the conducting airway”
BackgroundExGen 500 is an efficient vector for gene delivery to lung epithelial cells in vitro and in vivo
Ferrari, S., Moro, E., Pettenazzo, A., Behr, J., Zacchello, F., & Scarpa, M. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300503 · Cited by 256 · cited 1×
“Two days post infection, ferrets were killed and the lungs fixed by intratracheal perfusion of fixative solution, excised en bloc, processed, and stained with X-Gal as described by Ferrari and colleague”
Method
Cited by
Items 201–244 of 244
Cutting, G. R. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00062-8 · Cited by 3
Gene therapy in vascular surgery comes of age
Yonemitsu, Y., Komori, K., Sueishi, K., & Sugimachi, K. (2002) · Surgery · doi:10.1067/msy.2002.119967 · Cited by 3
Uta Griesenbach, D., McLachlan, G., Sinadinos, A., Cheminay, C., Ashour, J., Cox, J., Schwotzer, D., Vyhnal, K. K., Gupta, A., Chan, M., et al. (2025) · Molecular Therapy Advances · doi:10.1016/j.omta.2025.201655 · Cited by 2
“13,14 However, due to their short duration of expression and strong immunogenicity, 15 Sendai virus vectors, similar to adenoviral and AAV vectors, have not been useful for CF gene therapy to date.”
Sueishi, K., Onimaru, M., & Nakashima, Y. (2009) · Springer eBooks · doi:10.1007/978-4-431-78847-8_27 · Cited by 2
Fujiwara, T., Urata, Y., & Tanaka, N. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-879-9_13 · Cited by 3
Utility of Adenoviral Vectors in Animal Models of Human Disease II
Pickles, R. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800276-6.00025-5 · Cited by 2
Harada, Y., & Yonemitsu, Y. (2010) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.130.1519 · Cited by 2
Wiegand, M. A., & Neubert, W. J. (2013) · Springer eBooks · doi:10.1007/978-4-431-54556-9_4 · Cited by 2
Selective CCR2B receptor antagonists based on indole-2-carboxylic acid
AstraZeneca (2001) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.11.1.145 · Cited by 2
Gentherapie der zystischen Fibrose
Coutelle, C. C., & Bigger, B. (2001) · Der Internist · doi:10.1007/s001080170056 · Cited by 2
Gene Therapy for Lung Diseases
Alton, E. W. F. W., Davies, J. C., & Geddes, D. M. (2006) · Humana Press eBooks · doi:10.1007/978-1-59259-963-9_28 · Cited by 1
“One advantage of vectors such as Sendai virus is the direct cell entry via membrane fusion, which bypasses the endosome, allowing the virus to avoid degradation (Yonemitsu, 2000) .”
BackgroundResultInfluentialCytokines during the pathogenesis of bronchiolitis obliterans syndrome
Belperio, J. A., Keane, M. P., & Strieter, R. M. (2003) · Current Opinion in Organ Transplantation · doi:10.1097/00075200-200309000-00003 · Cited by 2
Reprogramming the Neurosciences
Lü, J. (2014) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.1000e124 · Cited by 1
“SeV-based vector has been used in clinical gene therapy for cystic fibrosis [10,11] and vaccine delivery [12].”
MethodFibroblast Growth Factor in Extremities
Tanaka, M., & Yonemitsu, Y. (2017) · Springer eBooks · doi:10.1007/978-981-10-2744-4_10 · Cited by 1
Efficient transduction of melanoma cells with Sendai viral vectors
Yılmazer, A., Taheri, H., & Can, A. (2017) · Turkish Bulletin of Hygiene and Experimental Biology · doi:10.5505/turkhijyen.2017.98705 · Cited by 1
King, M., & Zayas, J. G. (2004) · Pediatric Pulmonology · doi:10.1002/ppul.70059 · Cited by 1
“(18), in a study in which mucolytic treatments allowed for better access of vectors for gene therapy, although the transfer of certain viral vectors appeared to be unaffected by mucus (19).”
BackgroundA new gene transfer vector for the lung
Caplen, N. J. (2000) · Molecular Medicine Today · doi:10.1016/s1357-4310(00)01823-2 · Cited by 1
Cystic fibrosis: potential options for gene-directed therapies
Moraes, T., & Downey, G. (2004) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2004.11.009 · Cited by 4
Efficient Transfection of Sendai Virus Vector to Mouse Pancreatic Stem Cells in the Floating State
Oishi, K., Noguchi, H., Yukawa, H., Inoue, M., Miyamoto, Y., Iwata, H., Hasegawa, M., & Hayashi, S. (2010) · Cell Transplantation · doi:10.3727/096368910x509022 · Cited by 1
Stevens, C. S., Carmichael, J. C., Watkinson, R., Kowdle, S., Reis, R. A., Hamane, K., Jang, J., Park, A., Pernet, O., Khamaikawin, W., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.03.592383 · Cited by 1
Novel vector improves efficiency of gene transfer to the airway epithelium
Pickles, R. J. (2000) · Respiratory Research · doi:10.1186/rr-2001-68535
Fusaki, N. (2011) · Wiley eBooks · doi:10.1002/9781118147177.ch6
Ignáth, I. (2011) · SZTE Repository of Dissertations (University of Szeged) · doi:10.14232/phd.746
“β-Galactosidase staining β-Galactosidase activity was detected by in situ staining (Yonemitsu et al., 2000).”
BackgroundNanotechnology for Gene Therapy – HVJ ‐ E Vector
Hironori Nakagami, A., Tabata, Y., & Kaneda, Y. (2003) · Nanotechnologies for the Life Sciences · doi:10.1002/9783527610419.ntls0120
N-substituted acetonitrile inhibitors of cathepsin L
Ab, A. (2001) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.11.1.149
Pushing the envelope in the lung
Flotte, T. R. (2010) · Gene Therapy · doi:10.1038/gt.2010.132
Mukai, H., Kawakami, S., & Hashida, M. (2008) · Drug Delivery System · doi:10.2745/dds.23.454
Gene Therapy for Tracheal Stenosis Using Sendai Virus Vector
Mizokami, D., Araki, K., & Shiotani, A. (2015) · Koutou (THE LARYNX JAPAN) · doi:10.5426/larynx.27.51
Tanaka, M., & Yonemitsu, Y. (2016) · International Journal of Nursing & Clinical Practices · doi:10.15344/2394-4978/2016/174
“The bulk of experimental data related to the prototypic FGF-2 have been obtained in an animal modelin vivo to establish the potential for gene therapy trials in humans with PAD[19,20].”
BackgroundInfluentialStrategies to increase gene transfer to the lung
Larsen, M. D. B. (2011) · Spiral (Imperial College London) · doi:10.25560/6379 · Cited by 1
“In the ferret lung, SeV has been shown to transfect up to 80% of airway epithelial cells and in the nasal epithelium of CF knockout mice the chloride transport defect was partially restored following SeV-CFTR gene transfer [162,163].”
BackgroundGene therapy in cysticfibrosis
Armstrong, D. K., Cunningham, S., & Davies, J. C. (2015)
Cellular models of human brain disorders from skin to brain
Shahsavani, M. (2018) · Figshare
TBHEB 2017-2 Vol 74 Full Printed Journal
Ercömart, U. (2017) · Turkish Bulletin of Hygiene and Experimental Biology · doi:10.5505/turkhijyen.2017.82356
Klefenz, H. (2002) · Wiley eBooks · doi:10.1002/3527600124.refs
Huang, J., Wang, H., & Ham, H. (2011) · InTech eBooks · doi:10.5772/19590
“Efficient gene transduction into various primary cultured cells and tissues by recombinant virus vector has been reported [18-22].”
BackgroundNagai, Y. (2002) · Encyclopedia of Molecular Biology · doi:10.1002/047120918x.emb1399
Waring, W. S., & Oliver, J. J. (2002) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.1177/1478271520023202011
“In the respiratory tract of mice and ferrets 35 and cultured human nasal epithelial cells, the Sendai virus results in efficient gene transfer that is significantly better than that achieved with liposomes or adenovirus techniques.”
Utility of Adenoviral Vectors in Animal Models of Human Disease II
Pickles, R. J. (2002) · Elsevier eBooks · doi:10.1016/b978-012199504-1/50020-1
Gene Therapy in Nonneoplastic Lung Disease
Allen, T. C., & Cagle, P. T. (2008) · Molecular pathology library · doi:10.1007/978-0-387-72430-0_48
Rôle de SLC6A14 dans la physiopathologie pulmonaire de la mucoviscidose
Mercier, J. (2021) · theses.fr (ABES) · doi:10.70675/6e115649zd82ez404azba02zb48dd44c464f · Cited by 1
Phillips, M. A., Lei, L., Kulhánková, K., Gingerich, M. C., Loza, L. I. M., Vu, A., He, B., Thornell, I. M., & McCray, P. B. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102975 · Cited by 1
“24,25 Because the Sendai virus is a mouse path-ogen and the virus was replication competent, inflammatory responses were expected and observed in the murine, but not in non-rodent, studies.”
Assessment of F/HN-pseudotyped lentiviral vector following intravenous delivery to mice
Bell, R. V., Faulkner, N., Sinadinos, A., Meng, C., Castells, E., Viegas, M. A., Hyde, S. C., Gill, D. R., Alton, E. W. F. W., & Uta Griesenbach, D. (2026) · Gene Therapy · doi:10.1038/s41434-026-00623-3
Metadata
- Authors
- Yonemitsu, Y., Kitson, C., Ferrari, S., Farley, R., Griesenbach, U., Judd, D., Steel, R., Scheid, P., Zhu, J., Jeffery, P. K., Kato, A., Hasan, M. K., Nagai, Y., Masaki, I., Fukumura, M., Hasegawa, M., Geddes, D. M., & Alton, E. W. F. W.
- Affiliations
- Imperial College London (GB)
- National Institute of Infectious Diseases (JP)
- Kyushu University (JP)
- ID Pharma (Japan) (JP)
- Corresponding author
- Alton, Eric W.F.W.
- ORCID
- Venue
- Nature Biotechnology
- Published
- 2000-09
- Volume
- 18
- Issue
- 9
- Pages
- 970-973
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W1553961669
- Cited by
- 244
- References
- 25
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 5 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 2 · 2019: 3 · 2018: 4 · 2017: 10 · 2016: 11 · 2015: 5 · 2014: 7 · 2013: 11 · 2012: 8
- FWCI
- 10.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Keywords
- cystic fibrosis gene therapy, nasal epithelial cells, cationic liposomes, ferrets, mice
- MeSH terms
- Adenoviridae, Animals, Bronchi, Cell Line, Cells, Cultured, Cystic Fibrosis, Dogs, Dose-Response Relationship, Drug, Epithelium, Female, Ferrets, Genetic Vectors, Humans, Liposomes, Luciferases, Lung, Male, Mice, Inbred BALB C, Mucous Membrane, Nasal Mucosa, Receptors, Cell Surface, Sheep, Time Factors, Trachea, Transfection, Gene Transfer Techniques, Respirovirus, COS Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.